Short Interest in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Declines By 73.6%

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) was the target of a significant decrease in short interest during the month of June. As of June 30th, there was short interest totaling 74,316 shares, a decrease of 73.6% from the June 15th total of 281,382 shares. Currently, 1.7% of the shares of the company are sold short. Based on an average daily volume of 129,618 shares, the days-to-cover ratio is presently 0.6 days.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a report on Tuesday, April 21st. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has an average rating of “Sell”.

Institutional Trading of Galmed Pharmaceuticals

An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. Two Sigma Investments LP purchased a new stake in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 21,200 shares of the biopharmaceutical company’s stock, valued at approximately $29,000. Two Sigma Investments LP owned 1.28% of Galmed Pharmaceuticals as of its most recent SEC filing. Hedge funds and other institutional investors own 76.14% of the company’s stock.

Galmed Pharmaceuticals Trading Down 1.8%

Shares of NASDAQ GLMD traded down $0.01 during midday trading on Friday, hitting $0.56. 25,422 shares of the company’s stock were exchanged, compared to its average volume of 122,764. Galmed Pharmaceuticals has a 12-month low of $0.41 and a 12-month high of $2.34. The company has a market cap of $3.07 million, a price-to-earnings ratio of -0.45 and a beta of 0.75. The business’s fifty day moving average price is $0.60 and its two-hundred day moving average price is $0.65.

Galmed Pharmaceuticals (NASDAQ:GLMD) last announced its earnings results on Wednesday, July 8th. The biopharmaceutical company reported $0.29 earnings per share for the quarter.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials.

In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders.